Last mentioned: Apr 21, 2026
Coherus BioSciences is set to report Q4 2025 earnings as it completes its strategic transition into a pure-play oncology firm. Investors are focused on the commercial ramp of Loqtorzi and the market share recovery of the Udenyca franchise following the launch of its Onbody injector.
A widespread media narrative is challenging the clinical hegemony of statins, highlighting a perceived lack of transparency regarding side effects and alternative cardiovascular therapies. This shift in public discourse signals a growing demand for patient autonomy that could impact the long-term market share of traditional lipid-lowering blockbusters.
This page surfaces every story mentioning Amgen across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Amgen was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |